News
IMV
--
0.00%
--
IMV to Participate in Two Upcoming Investor Events
IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV's executive management team will...
BusinessWire · 01/04 09:05
Benzinga Pro's Top 5 Stocks To Watch For Monday, Dec. 28, 2020: IDEX, CLH, IMV, ATIF, OSMT
Today's 5 Stock Ideas:  Ideanomics (IDEX) - A play on electric ride-hailing vehicles in China. Shares were up 20% in pre-market action Monday following news of an initial 2,000-unit order by Didi, BYD
Benzinga · 12/28/2020 13:18
IMV's vaccine candidate potentially effective against COVID-19, shares up 16%
IMV (IMV) rises 16% premarket after providing an update on the development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection. The Company has successfully completed preclinical safety, GLP toxicology
Seekingalpha · 12/28/2020 12:48
IMV Shares Surge After COVID Vaccine Program Update
IMV shares soared Monday after the Canadian biotech updated progress on its coronavirus vaccine program, adding it will being preclinical studies on the new COVID variant first identified in the United Kingdom.
TheStreet.com · 12/28/2020 12:38
IMV Reports Update on COVID-19 Vaccine Program
--Vaccine candidate is stable at 2�C to 8�C and room temperature for at least 3 months and ongoing
BusinessWire · 12/28/2020 09:05
BTV Shines a Light on Companies to Invest In
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - BTV-Business Television spotlights the newest mining, cannabis, tech and pharmaceutical companies for investment opportunity.Discover Compa...
Newsfile · 12/10/2020 11:00
TMX Group, IMV, C-Suite at The Open
TORONTO, Dec. 9, 2020 /CNW/ - Fred Ors, CEO, IMV Inc.
CNW Group · 12/09/2020 15:40
Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace
Biotech stocks headed higher in the week ended Dec. 5 as broader market optimism pervaded into the sector. The sector also continued to get support from vaccine-related positive news flow.
Benzinga · 12/06/2020 13:41
Durable Clinical Benefits Induced by IMV's T Cell Therapy in Combination With Merck's Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting
--PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of 86 % associated with long duration of clinical benefits
BusinessWire · 12/06/2020 10:15
Durable Clinical Benefits Induced by IMV's T Cell Therapy in Combination With Merck's Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting
--PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of 86 % associated with long duration of clinical benefits
BusinessWire · 12/06/2020 10:15
CRWD, ZS, WDR and OMER among premarket gainers
Phoenix New Media (FENG) +115%.Lizhi (LIZI) +97% on collaboration with Xpeng MotorsEver-Glory International Group (EVK) +85%.Nesco Holdings (NSCO) +51% after announcing acquisition of Custom Truck One Source for $1.475B.Cyanotech Corporation (CYAN) +42%.Waddell
Seekingalpha · 12/03/2020 13:27
IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%
IMV (IMV) announces updated data from a Phase 2 clinical trial, DeCidE1, evaluating DPX-Survivac, combined with intermittent low-dose cyclophosphamide (chemo agent), in patients with recurrent advanced platinum-sensitive and platinum-resistant ovarian
Seekingalpha · 12/03/2020 12:48
The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2)
Benzinga · 12/03/2020 12:46
IMV Announces Data From Phase 2 Study Of DPX-Survivac; Says 37% Of Patients Experienced Clinical Benefits Lasting Over 6 Months
37% (7/19) patients experienced clinical benefits lasting over 6 months 12-month overall survival rate of 66.1% Translational data confirms survivin-specific CD8+ T cell immune response in 87% of
Benzinga · 12/03/2020 12:45
IMVs Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
Business Wire · 12/03/2020 12:10
IMV's Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
--12-month overall survival rate of 66.1%
BusinessWire · 12/03/2020 09:10
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday.
Benzinga · 11/29/2020 13:59
IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the Company will host a key opinion leader (KOL) webcast on the treatment options in ovarian cancer and competitive landscape within the disease state on Thursday, December 3, 2020 at 8.00am Eastern Time.
Business Wire · 11/13/2020 12:05
IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the Company will host a key opinion leader (KOL) webcast on the treatment options in ovarian cancer and competitive landscape within the disease state on Thursday, December 3, 2020 at 8.00am Eastern Time.
BusinessWire · 11/13/2020 09:05
IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the Company will host a key opinion leader (KOL) webcast on the t...
BusinessWire · 11/13/2020 09:05
Webull provides a variety of real-time IMV stock news. You can receive the latest news about IMV Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.
More